4.7 Article

Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN

Journal

NEUROLOGY
Volume 77, Issue 4, Pages 393-398

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318227047f

Keywords

-

Funding

  1. NIH [R01-DC010367, R01-AG037491, R21-AG38736, R01-AG11378, P50-AG16574, R01-NS065782, P50-NS072187, R01-AG02651, C06 RR018898]
  2. Mayo Foundation
  3. Dana Foundation
  4. Cephalon, Inc.
  5. Allon Therapeutics, Inc.
  6. NIH/NIA
  7. Alzheimer's Association
  8. Mangurian Foundation
  9. Pacific Alzheimer Research Foundation (Canada)
  10. Association for Frontotemporal Dementia
  11. Amyotrophic Lateral Sclerosis Association
  12. CurePSP
  13. Consortium for Frontotemporal Dementia
  14. Elan/Janssen AI
  15. Baxter International Inc.
  16. Forest Laboratories, Inc.
  17. Allergan, Inc.
  18. CIHR
  19. Mayo Clinic Florida Research Committee
  20. Pfizer Inc
  21. NIH (NIDCD, NIA)

Ask authors/readers for more resources

Objective: To use multiple serial MRI to assess rates and trajectories of brain and hippocampal atrophy in subjects with frontotemporal dementia (FTD) with progranulin (GRN) or microtubule-associated protein tau (MAPT) gene mutations. Methods: In this case-control study, we identified 8 subjects with mutations in GRN and 12 subjects with mutations in MAPT who had at least 2 serial MRIs. Serial MRIs were registered to baseline MRI for each subject using 9 df registration and rate of whole brain atrophy was calculated using the boundary-shift integral. Hippocampal volume was measured using Freesurfer. Mixed effects linear regression models were used to model volume change over time in both groups after adjusting for head size, age at baseline, and disease duration at baseline. Results: The annual rate of whole brain atrophy in the MAPT subjects was 2.4% per year (95% confidence interval [CI] 1.9-2.8). The GRN subjects showed a higher rate of whole brain atrophy at 3.5% per year (95% CI 2.8-4.2; p = 0.01). Rates of hippocampal atrophy were not different across the groups (MAPT = 7.8% [95% CI 3.9-12], GRN = 6.5% [95% CI 1.7-11], p = 0.66). Rates of whole brain atrophy in GRN, and hippocampal atrophy in MAPT, were associated with age, with older subjects showing slower rates of atrophy (p = 0.01 and p = 0.001). Conclusions: Subjects with FTD with GRN mutations have a faster rate of whole brain atrophy than subjects with FTD with MAPT mutations, with similar rates of hippocampal atrophy. Rates of atrophy in both groups were associated with age. These findings are important for future treatment trials in FTD that use rates of atrophy as an outcome measure. Neurology (R) 2011; 77: 393-398

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available